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Objectives. We sought to determine the cost-effectiveness of the 
recommendations of cardiologists for the pharmacologic treat- 
ment of hypercholesterolemia. 
Background. Despite the publication of guidelines such as the 
report of the National Cholesterol Education Program Expert 
Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults, little is known about the national prescrib- 
ing practices of physicians and how they compare with the 
recommendations of cost-effectiveness analyses. 
Methods. Under the auspices of the Cardiovascular Norms 
Committee of the American College of Cardiology, a nationally 
representative sample of cardiologists was surveyed, and their 
recommendations for the pharmacologic treatment of hypercho- 
lesterolemia were assessed to determine cost-effectiveness. 
Results. The 346 responding cardiologists were reasonably 
representative of the membership of the American College of 
Cardiology. For the 12 hypothetical patients, the cardiologists 
recommended pharmacologic treatment more commonly in cases 
in which previously published studies estimated the treatment o 
be more cost-effective, although there was a tendency to recom- 
mend such treatment for primary prevention even when it was 
estimated to cost well over $100,000/year of life saved. 
Conclusions. These findings suggest that the cardiologists' 
pharmacologic recommendations for lowering lipids are corre- 
lated with published cost-effectiveness analyses. However, sub- 
stantial variation in their recommendations remains, with some- 
what less aggressive treatment for secondary prevention and more 
aggressive treatment for primary prevention than would be rec- 
ommended on the basis of cost-effectiveness analyses. 
(J Am Coll Cardio11996;27:1232-7) 
Since the publication of the first Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Choles- 
terol in Adults (1), several studies (2-6) have examined 
physicians' compliance with these guidelines. However, the 
concordance of physicians' practices in the prescription of 
cholesterol-lowering drugs with published cost-effectiveness 
analyses of pharmacologic management of hypercholesterol- 
emia (7-14) is less known. 
The purpose of this study was to survey the cholesterol- 
lowering prescription practices of a representative sample of 
American cardiologists and to assess the cost-effectiveness of 
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these practices. Our data suggest that, at least for the prescrip- 
tion of cholesterol-lowering drugs, cardiologists' practices gen- 
erally are reasonably consistent with recommendations that 
would be based on cost-effectiveness considerations. 
Methods  
The Cardiovascular Norms Committee of the American 
College of Cardiology was mandated to perform surveys of a 
representative sample of American cardiologists o learn more 
about their practice patterns. The number of cardiologists to 
be surveyed was calculated to ensure that the accuracy of any 
reported results would be within 5% in either direction of the 
true rate. The necessary sample Size was calculated based on 
the width of 95% confidence intervals, assuming that 40% of 
respondents would reply affirmatively, adjusting for sampling 
from a finite population and increasing the sample size to 
account for an assumed 60% response rate to the survey. 
These considerations suggested that 603 (6.3%) of the 9,574 
cardiologists comprising the American College of Cardiology 
should be sampled. 
The same proportion (6.3%) of cardiologists was randomly 
selected in seven geographic regions. Two other regions were 
slightly oversampled (8.1% and 7.8%) to ensure that at least 33 
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cardiologists would be contacted in each region, thus allowing 
for regional comparisons. 
In a 1992 survey this sample of cardiologists was asked to 
describe their recommendations for diet and drug therapy for 
12 hypothetical patients with lipid abnormalities. Cardiologists 
were informed that the survey was not a test of knowledge, and 
they were asked to answer questions as they would commonly 
provide treatment in their primary work setting, assuming that 
risk factors and contraindications to therapy were absent 
unless otherwise mentioned. They were to assume that triglyc- 
eride levels were measured in the fasting state. 
Nonrespondents were sent one reminder letter. Of the 603 
cardiologists, 346 (56%) responded and recommended drug 
treatment with varying frequencies, depending on the case 
scenario. 
These respondents represented the overall membership of 
the American College of Cardiology in terms of age (mean 
48.8 years and 48.5 years, respectively) and gender (male 
94.6% and 94.3%, respectively). Based on data from another 
maifing survey to these 603 cardiologists, the respondents were 
similar to nonrcspondcnts in terms of work setting and annual 
number of hours of continuing medical education. Similar 
proportions of the respondents and nonrespondents per- 
formed diagnostic (58% vs. 64%, p = NS) and interventional 
(39% vs. 43%, p = NS) catheterizations, implanted pacemak- 
ers, programmed pacemakers, implanted automatic defibrilla- 
tors and performed tilt-table testing. Respondents were signif- 
icantly less likely to perform invasive lectrophysiologic testing 
(6% vs. 13%, p < 0.01), but were significantly more likely to 
perform echocardiograms (86% vs. 75%, p < 0.01) or radio- 
nuclide procedures (49% vs. 39%, p = 0.05). 
Because oversampling and regional differences in prescrib- 
ing habits were minimal, the prescribing rates reported from 
this survey were directly calculated as proportions of respon- 
dents. No adjustments were made for the weighted sampling 
scheme. 
Members of the Cardiovascular Norms Committee were 
asked to send questionnaires describing the same 12 case 
scenarios to two individuals whom they considered to be lipid 
experts at their own institutions. Responses were received 
from 18 of these lipid experts. The case scenarios were as 
follows. 
Cases with known coronary heart disease: 
Case A. A 53-year old postmenopausal woman experienced stable 
exertional angina 6 months before being referred to you. Workup 
revealed iffuse three-vessel coronary artery disease. Her symptoms 
are easily controlled with medication. She is 15% overweight. Her 
family history is positive for premature myocardial infarctions. She has 
been on a restricted diet that stabilized serum lipid levels: total 
cholesterol 290 mg/dl; low density lipoprotein (LDL) cholesterol 200 
mg/dl; high density lipoprotein (HDL) cholesterol 32 mg/dl; triglycer- 
ides 290 mg/dl. 
Case B. A 50-year old woman had an anterior myocardial infarction 
during the early morning. She has a 5-year history of diabetes 
successfully managed with diet and glyburide. Her family history is 
positive for diabetes and premature myocardial infarctions on her 
mother's ide. She is moderately overweight. She has been on a 
restricted iet that stabilized serum lipid level: total cholesterol 210 
mg/dl; LDL cholesterol 128 mg/dl; HDL cholesterol 30 mg/dl; triglyc- 
erides 260 mg/dl. 
Case C A 78-year old man developed nonexertional chest pain. His 
exercise treadmill test was borderline positive. Coronary arteriography 
revealed irregular coronary vessel lumen with no lesion >30% reduc- 
tion diameter. His symptoms have resolved. He has been on a 
restricted iet that stabilized serum lipid level: total cholesterol 260 
mg/dl; LDL cholesterol 190 mg/dl; HDL cholesterol 38 mg/dl; triglyc- 
erides 160 mg/dl. 
Case/9. A 62-year old woman had an anterior myocardial infarc- 
tion. Her recovery was uneventful. She has been on a restricted iet 
that stabilized her serum lipid level: total cholesterol 210 mg/dl; LDL 
cholesterol 125 mg/dl; HDL cholesterol 40 mg/dl; triglycerides 225 
mg/dl. 
Case E. A 70-year old man underwent coronary artery bypass graft 
surgery four times for severe diffuse coronary artery disease. He has 
had two non-Q-wave myocardial infarctions. He stopped smoking 1 
year earlier. He has been on a restricted iet that stabilized his serum 
lipid level: total cholesterol 230 mg/dl; LDL cholesterol 150 mg/dl; 
HDL cholesterol 35 mg/dl; triglycerides 225 mg/dl. 
Case F. A 61-year old man has angina pectoris and severe three-vessel 
disease, which is deemed inoperable. His family history is positive for 
coronary artery disease. He has been on a restricted diet that stabilized his 
serum lipid level: total cholesterol 205 mg/dl; LDL cholesterol 145 mg/dl; 
HDL cholesterol 38 mg/dl; triglycerides 158 mg/dl. 
Case G. A 57-year old man had an inferior wall Q-wave myocardial 
infarction. His recovery was uneventful. He has been on a restricted 
diet that stabilized his serum lipid level: total cholesterol 240 mg/dl; 
LDL cholesterol 160 mg/dl; HDL cholesterol 48 mg/dl; triglyeerides 
160 mg/dl. 
Case H. A 45-year old man experienced the onset of angina at rest. 
He was adopted and the family history is unknown. He has been on a 
restricted iet that stabilized his serum lipid level: total cholesterol 820 
mg/dl; LDL cholesterol 60 mg/dl; HDL cholesterol 15 mg/dl; triglyc- 
erides 4560 mg/dl. 
Cases without known coronary heart disease: 
Case L A 44-year old man is referred for evaluation after his 
48-year old brother had a myocardial infarction. The family history is 
positive for premature ischemic heart disease. He has no evidence of 
coronary artery disease by history, physical examination, electrocardi- 
ography or treadmill testing. He presents with serum lipid levels of: 
total cholesterol 290 mg/dl; LDL cholesterol 220 mg/dl; HDL choles- 
terol 45 mg/dl; triglycerides 122 mg/dl. 
Case J. A 55-year old, mildly obese, diabetic woman is referred for 
evaluation due to atypical chest pain. Her diabetes has been controlled 
with insulin for more than 10 years. Cardiac evaluation is normal, 
including exercise thallium imaging. Her family history is positive for 
diabetes. She presents with serum lipid levels of: total cholesterol 260 
mg/dl; LDL cholesterol 170 mg/dl; HDL cholesterol 35 mg/dl; triglyc- 
erides 275 mg/dl. 
Case K. A 38-year old man has his cholesterol measured at a 
business meeting and referred himself for evaluation. He exercises 
regularly and is in excellent physical condition. His physical examina- 
tion, electrocardiogram and treadmill test are normal. He presents 
with serum lipid levels of: total cholesterol 230 mg/dl; LDL cholesterol 
155 mg/dl; HDL cholesterol 40 mg/dl; triglycerides 175 mg/dl. 
Case L. An asymptomatic 33-year old woman referred herself or 
evaluation. Her father had a myocardial infarction at age 54. She is in 
excellent health. She presents with serum lipid levels of: total choles- 
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tero1234 mg/dl; LDL cholesterol 160 mg/dl; HDL cholesterol 35mg/dl; 
triglycerides 195 mg/dL 
Cost-effectiveness calculations. To calculate the cost- 
effectiveness ratios of the drug therapy recommended bythe 
cardiologists for each of the cases, we used previously pub- 
lished cost-effectiveness analyses of pharmacologic treatment 
for primary and secondary prevention of coronary artery 
disease (7,8). Baseline cost-effectiveness ratios, expressed as 
estimated costs per year of life saved for each case, were 
derived from an analysis of HMG-coenzyme A reductase 
inhibition by 20 mg of lovastatin (8). In that report, costs per 
year of life saved of 20, 40 and 80 mg of lovastatin given every 
day were tabulated by gender, 10-year age groups and pretreat- 
ment cholesterol levels <250 mg/dl or >-250 mg/dl for second- 
ary prevention. For primary prevention, costs per year of life 
saved were tabulated by gender, 10-year age groups, pretreat- 
ment cholesterol levels of 250 to 299 mg/dl or ->300 mg/dl and 
three other isk factors--diastolic blood pressure (<95 mm Hg, 
95 to 104 nun Hg and ->105 mm Hg), current smoking status and 
percent of ideal weight (<110%, 110% to 129%, ->130%). 
Published cost-effectiveness analyses of cholesterol reduction 
have not included family history or diabetes as risk factors, so we 
sought a simplified approach to adjust prior analyses to our case 
scenarios, because we were interested in the extent o which 
published ata may have affected physicians' practices. Based on 
our own analysis of the Framingham data and a review of the 
published reports (15), we estimated that a woman with diabetes 
would have about he same risk of coronary artery disease as that 
of a man of the same age and with other similar isk factors; in a 
man, the increased risk associated with diabetes was considered to
be about equal to the risk of smoking as compared with not 
smoking. The independent relative risk associated with a family 
history of coronary artery disease is about 1.8 (16-18), which is 
similar to diabetes, and hence also similar to a man's increased 
risk associated with smoking. 
To estimate the cost-effectiveness ratios for the other drugs 
chosen by the cardiologists, we multiplied the cost- 
effectiveness ratios for lovastatin by coefficients derived from 
the costs per 1% reduction of LDL cholesterol computed by 
Schulman et al. (7) in their clinical model: costs per 1% 
reduction of LDL cholesterol were $139 for niacin, $177 for 
20 mg of lovastatin, $289.90 for gemfibrozil, $334.54 for 
probucol and $347 for cholestyramine. The coefficients we 
calculated were the ratios of the cost per 1% reduction of LDL 
cholesterol for drug divided by the cost per 1% reduction of 
LDL cholesterol for 20 mg of lovastatin given every day. The 
resulting coefficients were 0.785 for niacin ($139/$177), 1.64 for 
gemfibrozil ($289.90/$177), 1.89 for probucol ($334.54/$177) 
and 1.96 for cholestyramine ($347/$177). To the extent o 
which increasing doses of lovastatin and other medications cost 
relatively more per percent reduction i  LDL cholesterol, all of 
the calculated cost-effectiveness ratios were somewhat more 
favorable than if patients were put on high dose medication to 
lower cholesterol very aggressively. However, because all but 
one case had moderate hypercholesterolemia, at most, this 
approach to calculating cost-effectiveness was believed to be 
preferable to arbitrary assumptions about all patients being 
titrated to some specific holesterol level. 
Finally, to summarize physician preferences for one drug 
over another, the median cost-effectiveness ratio for drug 
therapy for each case scenario was calculated. For example, for 
a given case, if the cost-effectiveness ratio of 20 mg of 
lovastatin was $1,000 per year of life saved and 20% of the 
cardiologists who decided that drug therapy was indicated 
prescribed lovastatin, 20% prescribed gemfibrozil and 60% 
niacin, the median cost-effectiveness ratio of the cardiologists' 
drug therapy for that case would have been $1,000 x 0.785, or 
$785 per year of life saved. Note that his analysis calculates the 
median marginal cost-effectiveness of drug therapy for each case; 
physicians who did not recommend medications for a specific ase 
do not contribute to the calculation. The use of median values 
reduced the influence of occasional physicians who might choose 
very expensive drugs; analyses using the mean of the individual 
cost-effectiveness ratios of each physician gave qualitatively sim- 
ilar results. Median cost-effectiveness ratios of the drug therapy 
recommended bythe lipid experts were calculated similarly as for 
drug therapy recommended bycardiologists. 
We computed the cost-effectiveness ratios in dollars per 
year of life saved for the pharmacologic therapy recommended 
for each case of primary and secondary prevention, with the 
exception of Case C, whose description was misleading to 
many cardiologists and made it impossible for them to classify 
the case in a primary or a secondary prevention model. 
Statistical analysis. Comparisons between cardiologists 
and lipid experts were performed using the Wilcoxon test for 
cost-effectiveness ratios and the Fisher exact test for the 
proportions of respondents who would prescribe medications. 
Because of the multiple comparisons being examined, statisti- 
cal significance was defined as p < 0.01. 
Ninety-five percent confidence intervals were computed for 
median cost-effectiveness ratios using a multistep simulation 
process. First, the usual 95% confidence intervals were calcu- 
lated for the proportions of cardiologists prescribing each 
medication. Then, a proportion was generated atrandom from 
within each confidence interval, with the restriction that the 
proportions summed to 1. Finally, these simulated proportions 
were used to generate new, "simulated" ecisions from each of 
the participating cardiologists. A simulated median cost- 
effectiveness ratio was calculated based on these decisions. 
This simulation was repeated 1,000 times, and 95% confidence 
intervals were taken from the appropriate extremes of these 
1,000 replications. Because only five medications were consid- 
ered, the median cost could only take on one of five possible 
values. Therefore, in most cases, the estimated median will 
be found to be very stable in the sense that the upper and 
lower confidence limits will be exactly equal to the estimated 
median. 
Results 
The clinical characteristics, risk factor profile and total 
cholesterol levels for secondary prevention cases (A through 
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Table 1. Clinical Characteristics and Risk Factors of Primary and Secondary Prevention Cases 
Risk Factors 
Total 
Age (yr)/ Cholesterol Family History 
Case Gender (mg/dl) Smoking Hypertension Obesity. Diabetes of CAD 
Primary Prevention 
A 53/F 290 - - + - + 
B 50/F 210 - - + + + 
D 62/F 210 - - - 
E 70/M 230 + - - 
F 61/M 205 . . . .  + 
G 57/M 240 - - - 
H 45/M 820 . . . . .  
Secondary Prevention 
I 44/M 290 - - - ~- 
J 55/F 260 - - + + - 
K 38/M 230 . . . .  
k 33/F 234 - - - + 
CAD = coronary, artery, disease; - = negative; + = positive. 
H) and primary prevention cases (I through L) are summarized 
in Table 1. The proportion of cardiologists who recommended 
various forms of medications varied widely from case to case 
(Table 2), with lovastatin usually the most popular medication 
for both primary and secondary prevention. The median 
cost-effectiveness ratios of the cardiologists' drug therapy 
recommendation for each of the secondary prevention cases 
(A through H) was $36,000 or less per year of life saved. For 
primary prevention cases (I through L), costs per year of life 
saved for recommended pharmacologic treatment were much 
less favorable, even for case J with two risk factors, because of 
her female gender. 
The median cost-effectiveness ratios of cardiologists' drug 
therapy recommendations for secondary prevention cases and 
primary prevention cases (Fig. 1) showed a clear inverse 
relation between the cost per year of life saved of a pharma- 
cologic treatment and the percentage of cardiologists who 
chose it. Fewer cardiologists considered rug treatment for 
primary prevention than for secondary prevention, and the 
percentage of cardiologists who thought that drug treatment 
was appropriate for the most expensive secondary prevention 
case (case D) was 24%, whereas the highest percentage of 
cardiologists who considered rug treatment for a primary 
prevention case was 31% (case I). 
The lipid experts' responses were generally similar to those 
of the cardiologists. Although a larger percentage of lipid 
experts recommended drug treatment for cases D and F (p < 
0.01), the cost-effectiveness ratios of the recommended treat- 
ment strategies for these two cases were not significantly 
different for the cardiologists compared with the lipid experts. 
The cost-effectiveness ratios for cases A and J were signifi- 
cantly lower for lipid experts than for cardiologists because the 
Table 2. Choices of Pharmacologic Therapy 
Medication 
% Prescribing Median Costs/Year 
Case Niacin Lovastatin Cholestyramine Gemfibrozil Other Medications of Life Saved* 
A 47 (14%) 165 (48%) 23 (7%) 90 (27%,) 3 (0.9%) 97 $ 3,500 
B 25 (7%) 14 (4%) 7 (2%) 129 (37%) 3 (0.9%) 51 $ 26,000 
D 25 (7%) 18 (5%) 9 (3%) 26 (8%) 2 (0.6%) 24 $ 36,000 
E 43 (13%,) 105 (31%) 20 (6%,) 67 (20%) 1 (0.3%) 70 $ 25,000 
F 32 (10%) 130 (38%) 22 (6%) 17 (5%) 1 (0.3%) 59 $ 17,000 
G 24 (7%) 149 (45%) 46 (14%) 10 (3%) 0 69 $ 17,000 
H 35 (11%) 74 (22%) 15 (5%) 164 (49%) 9 (3%) 90 Negative or 
minimal costs 
I II (3%) 71 (21%) 19 (6%) l (0.3%) 0 31 $ 370,000 
J 10 (3%) 26 (8%) 11 (3%) 50 (14%) 2 (0.6%) 29 $ 121,000 
K 1 (0.3%) 3 (0.9%) 0 1 (0.3%) 1 (0.3%) 1.5 $ 690,000 
L 0 1 (0.3%) 1 (0.3%) 2 (0.6%) 0 1.2 > $1,000,000 
*Simulated 95% confidence limits how that hese stimates of median costs are stable (i.e., upper limit equals lower limit equals reported median) for all but case 
D, where the cost could be as high as $59,000; case J, where cost could be as low as $74,000; and case K, where cost could be as low as $542,000 oras high as >$1,000,000. 
Confidence limits are not provided for cases H and L, where xact cost-effectiveness ratios are not presented. 
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Figure 1. Relation between the cost-effectiveness of 
drug treatment and the percentage of cardiologists 
who recommended drugs. Letters refer to individual 
cases. See Methods for details. 
lipid experts were more likely to prescribe niacin rather than 
lovastatin. 
Discuss ion  
In January 1988, the NCEP (1) guidelines were published. 
This step by the Expert Panel on Detection, Evaluation and 
Treatment of High Blood Cholesterol in Adults was the logical 
consequence of epidemiologic studies howing that total cho- 
lesterol and LDL cholesterol levels were independently asso- 
ciated with coronary artery disease rates and of randomized 
clinical trials that revealed a decrease in the incidence of 
coronary events in middle-aged men with high blood choles- 
terol who were assigned to cholesterol-lowering drugs. 
Physician practice patterns. These guidelines increased 
the percentage of physicians who considered total cholesterol 
a risk factor from 39% in 1983 to 99% in 1990 (2), and 
physicians reported treating serum cholesterol levels at lower 
levels in 1990 than in 1986 or 1983. Although more diversity 
remained among physicians in treating hypercholesterolemia 
than in treating hypertension, the evolution of physicians' 
practices in the early years of the NCEP was considered similar 
or even faster for hypercholesterolemia th n for hypertension 
in the early years of the National High Blood Pressure 
Education Program (3). 
However, the results of other studies were less optimistic. In 
1988, compliance with the NCEP recommendations fordocu- 
menting desirable total cholesterol values or appropriately 
responding to abnormal values among residents at the Metro- 
health Medical Center, Cleveland, Ohio, averaged 39% (4), 
and residents markedly overestimated their own compliance. 
In 1989 and 1990, 24% of physicians in Wisconsin still did not 
recognize 240 mg/dl as an elevated cholesterol level nor did 
they treat hypercholesterolemia in line with the recommenda- 
tions (5); no differences were observed among specialty groups. 
Interestingly, although dietary counselling for hypercholester- 
olemia was common among primary care physicians (6), low 
rates were observed for starting cholesterol-lowering medica- 
tions. Less dogmatic NCEP guidelines for drug therapy than 
for dietary therapy, as well as the lack of unanimity in the 
medical community about drug treatment for hypercholester- 
olemia, were considered as possible xplanations. 
Cost-effectiveness. In an era of concern about health care 
costs, it would have been surprising if the issue of the cost of 
pharmacologic treatment for hypercholesterolemia, high- 
lighted by specific ost-effectiveness analyses (7-13,19), did not 
affect the drug prescribing patterns of American physicians. 
The results of our study are consistent with this hypothesis and 
show a clear inverse relation between the cost-effectiveness of 
drug therapy and the percentage of cardiologists who would 
consider it. The costs per year of life saved reported in our 
results reflect the fact that, for secondary prevention, drug 
therapy is effective (20) and generally has favorable cost- 
effectiveness ratios. For primary prevention, cost-effectiveness 
ratios of drug therapy are favorable only in selected high risk 
subgroups (7-13,19). 
The fact that an inverse relation between cost-effectiveness 
ratios and the percentage ofcardiologists who considered rug 
therapy existed not only for primary prevention but also for 
secondary prevention, where cost-effectiveness ratios were 
more favorable overall, highlights physicians' current concern 
about he cost of their prescribing practices. A previous tudy 
(21) reported that physicians at a university hospital consid- 
ered that costs had an important influence on their prescribing 
behavior, even if most of them, when presented with specific 
situations, were unaware of the actual prices of the medica- 
tions they prescribed and seemed more influenced by what was 
routinely prescribed by others than by costs. Similarly, infor- 
mation on costs, as well as on clinical and pharmacologic 
issues, were shown to improve physicians' prescribing habits in 
another study (22). Our results also suggest hat published 
analyses on the cost-effectiveness of drug therapy may influ- 
ence practice patterns more so than trials of more aggressive 
interventions such as thrombolysis (23,24), as has been noted 
in the results of randomized clinical trials of cardiovascular 
drugs after acute myocardial infarction (25). 
A limitation of our study is that the two prior studies (7,8) 
from which we derived our cost-effectiveness ratios did not 
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consider any effects of cholesterol reduction on noncoronary 
death rates. Although meta-analyses of primary prevention 
trials (26-29) and analyses of low risk groups in both primary 
and secondary prevention trials (30,31) revealed higher rates 
of noncardiovascular deaths in men receiving cholesterol- 
lowering drugs, the largest secondary prevention trial found no 
increase in noncardiovascular deaths (20). Even if cost- 
effectiveness ratios for this study were recalculated toconsider 
possible noncoronary adverse effects, the inverse relation 
observed between the cost-effectiveness ratios of drug treat- 
ment and the percentage of physicians who would consider it 
would persist. 
Conclusions. Despite the consistent trend toward decreas- 
ing prescription use in patients with lower cost-effectiveness 
ratios, the thresholds for prescribing cholesterol-lowering 
drugs varied among cardiologists. Only -60% of cardiologists 
would prescribe drugs in secondary prevention cases in which 
the cost-effectiveness ratio was favorable, and -30% would 
prescribe medications inprimary prevention cases in which the 
ratio was estimated to be unfavorable. These findings in the 
"middle range" cases emphasize the need for more research to 
determine whether the estimated cost-effectiveness ratios are 
truly accurate and whether improved education programs 
influence practice based on the best available data. The effects 
of such research on prescription practices, as well as of the 
Second Report of the NCEP Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults 
(Adult Treatment Panel II) (32), will have to be evaluated. 
We are indebted to the American College of Cardiology and its Cardiovascular 
Norms Committee and to Lawrence S. Ganslaw, MBA of the American College 
of Cardiology. 
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